Publications by authors named "David T Dicker"

Claim this Profile
C
Corrigendum to "P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9" [Neoplasia, volume 23 (2021) 304325].
Xiaobing Tian, Nagib Ahsan, Amriti Lulla, Avital Lev, Philip Abbosh, David T Dicker

Neoplasia· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of TRAIL-Induced Mcl-1 and cIAP2 by c-Myc or Sorafenib Sensitizes Resistant Human Cancer Cells to TRAIL-Induced Death.
M Stacey Ricci, Seok-Hyun Kim, Kazuhiro Ogi, John P Plastaras, Jianhua Ling, David T Dicker

Cancer Cell· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
Joshua E Allen, Gabriel Krigsfeld, Luv Patel, Patrick A Mayes, David T Dicker

Mol Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells.
Amriti R Lulla, Yan Zhou, Marie D Ralff, Avital Lev, David T Dicker

Am J Cancer Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer and .
Jocelyn E Ray, Marie D Ralff, Aakash Jhaveri, Lanlan Zhou, David T Dicker

Cancer Biol Ther· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Discovery and clinical introduction of first-in-class imipridone ONC201.
Joshua E Allen, C Leah B Kline, Varun V Prabhu, Jessica Wagner, Jo Ishizawa, David T Dicker

Oncotarget· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-cancer efficacy including Rb-deficient tumors and VHL-independent HIF1α proteasomal destabilization by dual targeting of CDK1 or CDK4/6 and HSP90.
Shuai Zhao, Lanlan Zhou, David T Dicker, Avital Lev, Shengliang Zhang

Sci Rep· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A subset of CB002 xanthine analogs bypass p53-signaling to restore a p53 transcriptome and target an S-phase cell cycle checkpoint in tumors with mutated-p53.
Liz Hernandez Borrero, David T Dicker, John Santiago, Jennifer Sanders, Xiaobing Tian

Elife· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9.
Xiaobing Tian, Nagib Ahsan, Amriti Lulla, Avital Lev, Philip Abbosh, David T Dicker

Neoplasia· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRAIL receptor agonists convert the response of breast cancer cells to ONC201 from anti-proliferative to apoptotic.
Marie D Ralff, Aakash Jhaveri, Jocelyn E Ray, Lanlan Zhou, Avital Lev, David T Dicker

Oncotarget· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA.
Liz J Hernandez-Borrero, Shengliang Zhang, Amriti Lulla, David T Dicker, Wafik S El-Deiry

Cell Cycle· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
Varun V Prabhu, Mala K Talekar, Amriti R Lulla, C Leah B Kline, Lanlan Zhou, David T Dicker

Cell Cycle· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
Avital Lev, Amriti R Lulla, Brian C Ross, Marie D Ralff, Petr B Makhov, David T Dicker

Mol Cancer Res· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of Dopamine Receptors in the Anticancer Activity of ONC201.
Christina Leah B Kline, Marie D Ralff, Amriti R Lulla, Jessica M Wagner, Phillip H Abbosh, David T Dicker

Neoplasia· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
miR-6883 Family miRNAs Target CDK4/6 to Induce G Phase Cell-Cycle Arrest in Colon Cancer Cells.
Amriti R Lulla, Michael J Slifker, Yan Zhou, Avital Lev, Margret B Einarson, David T Dicker

Cancer Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.
Avital Lev, Amriti R Lulla, Jessica Wagner, Marie D Ralff, Joshua B Kiehl, David T Dicker

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.
Avital Lev, Safoora Deihimi, Elena Shagisultanova, Joanne Xiu, Amriti R Lulla, David T Dicker

Cancer Biol Ther· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor cells: silent predictors of metastasis.
LanLan Zhou, David T Dicker, Elizabeth Matthew, Wafik S El-Deiry, R Katherine Alpaugh

F1000Res· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Marie D Ralff, Christina L B Kline, Ozan C Küçükkase, Jessica Wagner, Bora Lim, David T Dicker

Mol Cancer Ther· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.
Jun Zhang, Lanlan Zhou, Shuai Zhao, David T Dicker, Wafik S El-Deiry

Cell Cycle· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and clinical introduction of first-in-class imipridone ONC201.
Joshua E Allen, C Leah B Kline, Varun V Prabhu, Jessica Wagner, Jo Ishizawa, David T Dicker

Oncotarget· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation.
Varun V Prabhu, Bo Hong, Joshua E Allen, Shengliang Zhang, Amriti R Lulla, David T Dicker

Cancer Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Deubiquitinase Inhibitor PR-619 Sensitizes Normal Human Fibroblasts to Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-mediated Cell Death.
Roslyn N Crowder, David T Dicker, Wafik S El-Deiry

J Biol Chem· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
C Leah B Kline, A Pieter J Van den Heuvel, Joshua E Allen, Varun V Prabhu, David T Dicker

Sci Signal· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multiplexed marker-based algorithm for diagnosis of carcinoma of unknown primary using circulating tumor cells.
Elizabeth M Matthew, Lanlan Zhou, Zhaohai Yang, David T Dicker, Sheldon L Holder

Oncotarget· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis